#61
|
||||
|
||||
Öèòàòà:
|
#62
|
|||
|
|||
 ñðàâíåíèè ñ ëåêàðñòâåííûìè ñðåäñòâàìè.
|
#63
|
||||
|
||||
Öèòàòà:
|
#64
|
||||
|
||||
Ðåïëèêà!
Ïîêà íå èìåþ íè âðåìåíè íè âîçìîæíîñòè ó÷àñòâîâàòü â äèñêóññèè (ãîòîâëþñü ê ãåíîäèàãíîñòèêå 2005), îäíàêî êîå -êòî ïåðåãèáàåò ïàëêó â "ïðàâåäíîì ãíåâå"
Öèòàòà:
Äàâàéòå íå áóäåì âñå îáîáùàòü à? Îïÿòü ñ âîäîé âûïëåñêèâàåì ðåáåíêà. |
#65
|
|||
|
|||
O kak!
 Íîâîñèáèðñêå íà÷íåòñÿ ïðîèçâîäñòâî ýôôåêòèâíîãî è íåäîðîãîãî àíòè-ÂÈ× ïðåïàðàòà.
 Íîâîñèáèðñêå â òå÷åíèå ãîäà áóäåò íà÷àòî ïðîìûøëåííîå ïðîèçâîäñòâî íîâîãî îòå÷åñòâåííîãî âûñîêîýôôåêòèâíîãî àíòè-ÂÈ× ïðåïàðàòà, ðàçðàáîòàííîãî â Ãîñóäàðñòâåííîì íàó÷íîì öåíòðå âèðóñîëîãè è áèîòåõíîëîãèè (ÃÍÖ ÂÁ) "Âåêòîð". Îá ýòîì âî âòîðíèê ñîîáùèë æóðíàëèñòàì çàâåäóþùèé îòäåëîì õèìèè ïðèðîäíûõ è áèîëîãè÷åñêè àêòèâíûõ ñîåäèíåíèé Íîâîñèáèðñêîãî èíñòèòóòà îðãàíè÷åñêîé õèìèè ÑÎ ÐÀÍ Íàðèìàí Ñàëàõóòäèíîâ, ïåðåäàåò ÐÈÀ "Íîâîñòè". Ãîäîâîé êóðñ ëå÷åíèÿ ýòèì ïðåïàðàòîì áóäåò ñòîèòü îò $300-600, ðàññêàçàë â ñâîþ î÷åðåäü çàâåäóþùèé ëàáîðàòîðèåé ðåòðîâèðóñîâ ÃÍÖ ÂÁ "Âåêòîð" Àíäðåé Ïîêðîâñêèé. " íàñòîÿùåå âðåìÿ óæå çàâåðøåíû äîêëèíè÷åñêèå èñïûòàíèÿ ïðåïàðàòà, åãî ñïåöèôè÷åñêàÿ àêòèâíîñòü ïîäòâåðæäåíà â ðÿäå çàðóáåæíûõ ëàáîðàòîðèé. Êëèíè÷åñêèå èñïûòàíèÿ ïðîéäóò â ïåðâîì è âòîðîì êâàðòàëå ñëåäóþùåãî ãîäà", - äîáàâèë Ïîêðîâñêèé. |
#66
|
||||
|
||||
Öèòàòà:
Ïîèñê â Pubmed ïî çàïðîñó IRS19, clinical trials, human: 1: Volgin AR, Demina IuV. [Experience of using bacterial lysate IRS 19 for the prophylaxis of the diseases of respiratory organs in organized groups] Zh Mikrobiol Epidemiol Immunobiol. 2005 May-Jun;(3):82-4. Russian. PMID: 16028523 2: Gunchikov MV, Vinnikov AK. [Immune preparation IRS-19 in the treatment of inflammation in the upper respiratory tracts] Vestn Otorinolaringol. 2001;(1):40. Russian. No abstract available. PMID: 11247247 3: Luchikhin LA, Beliakova LV, Gurov AV. [Prevention and treatment of upper respiratory tract infections with IRS-19 and polydex with phenylephrine] Vestn Otorinolaringol. 2000;(4):54-7. Russian. No abstract available. PMID: 11011582 4: Nowak D, Prozynski M, Pietras T, Stolarek R, Mazerant P, Leder M. Effect of bacterial extract, IRS-19, on the concentration of hydrogen peroxide and myeloperoxidase activity in nasal washings of patients with chronic bronchitis. Arch Immunol Ther Exp (Warsz). 1997;45(1):67-72. PMID: 9090443 5: Kaspar P, Petro W. [Inhalative immunostimulation in patients with chronic bronchitis] Z Hautkr. 1988;63 Suppl 4:64-6. German. PMID: 3075383 [PubMed - indexed for MEDLINE] Ñòàòüè â ðóññêèõ è ïîëüñêèõ æóðíàëàõ. Ê ñîæàëåíèþ, ó ìåíÿ íåò âîçìîæíîñòè èõ ïðî÷èòàòü. Íåìåöêàÿ ñòàòüÿ îïóáëèêîâàíà â 1988 ãîäó. |
#67
|
||||
|
||||
Âñå- òàêè èìååòñÿ êàêîé-òî ëîãè÷åñêèé ïàðàäîêñ- êîãäà ãîâîðèòñÿ î âîçìîæíîñòè íåìåäèêàìåíòîçíîãî âîçäåéñòâèÿ íà òîò ñàìûé ïðåñëîâóòûé îðãàíèçì- ñîëíöå, âîçäóõ, çàêàëèâàíèå, ðàçóìíîå ïèòàíèå êàê ïðîôèëàêòèêå ÷àñòûõ ïðîñòóä, íïðì., ñðàçó æå âîçíèêàåò âîçðàæåíèå àëüòåðàíòèâùèêîâ è äàþòñÿ èäåè ñòèìóëÿöèè èììóíèòåòà èììóíîìîäóëÿòîðàìè èëè ãîìåîïàòè÷åñêèìè ñðåäñòâàìè ( íó õòü ÁÀÄàìè ïî áëàòó), åñëè æå ãîâîðèøü î ìåäèêàìåíòîçíîì ëå÷åíèè çàáîëåâàíèé. òðåáóþùèõ îíîãî ( ò.å ëå÷åíèÿ) ñðàçó æå âîçíèêàåò àëüòåðíàòèâíàÿ âåðñèÿ ïðî çâåðñòâà ôàðììàôèè è óêðåïëåíèå èììóíèòåòà - ïî - âèäèìîìó. èììóíîìîäóëÿòîðàìè, ãîìåîïàòèåé è ÁÀÄàìè.. ×òî-òî çäåñü òå âÿæåòñÿ..
__________________
Ã.À. Ìåëüíè÷åíêî |
#68
|
||||
|
||||
Öèòàòà:
[Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì] ßäîâèòîå, õèìè÷åñêîå âåùåñòâî ñìåðòåëüíîé îïàñíîñòè – ïðåäóïðåæäåíèå êîìïàíèè «Ñèãìà Êåìèêàë Èíê» (Sigma Chemical Co.) íà êðîøå÷íîì 25 ìã ïóçûðüêå AÇT, ïîñòàâëÿåìîãî â íàó÷íî-èññëåäîâàòåëüñêèå ëàáîðàòîðèè. Âû î÷åâèäíî íå íàéäåòå ïîäîáíîãî ñîâåòà íà ÿðëûêå AÇT, êîòîðûé ïðîèçâîäèò "Ãëàêñî Ñìèò Êëÿéí" èëè â åãî ðåêîìåíäàöèè, ãäå åæåäíåâíàÿ äîçà óïîòðåáëåíèÿ â øåñòüäåñÿò ðàç âûøå. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#69
|
||||
|
||||
Ïðîñòèòå, íàâåðíîå çðÿ íå îäîáðèëà. Ìíå ïîêàçàëîñü, ÷òî Âû - ÑÏÈÄ-äèññèäåíò è ðàçäåëÿåòå ìíåíèå Ñàçîíîâîé.
Íàäåþñü, ÷òî àäìèíèñòðàöèÿ ñóìååò èñïðàâèòü ìîþ îøèáêó. |
#70
|
|||
|
|||
ß òîæå ñâÿçè ìåæäó ñîîáùåíèÿìè íå óâèäåë.
|
#71
|
|||
|
|||
Öèòàòà:
Ïî÷åìó îðãàíèçì «ïðåñëîâóòûé»? È ïîòîì, âåäü ñîëíöå, âîçäóõ, çàêàëèâàíèå – ÍÅ ÄÎÊÀÇÀÍÎ! Êàê òóò íà ôîðóìå âûðàçèëèñü ñàíêóðëå÷åíèå – õîðîøåå ïëàöåáî. |
#72
|
||||
|
||||
|
#73
|
|||
|
|||
Ãåðïåòè÷åñêèé öåíòð ìåíÿ ëè÷íî ãîìåîïàòèåé íå ëå÷èë. Ñìûñë òàì òàêîé - ñïåðâà àíàëèçû íà âñå èíôåêöèè, ïîòîì èììóíîãðàììà. Äàëåå ïî èììóíîãðàììå íàçíà÷àþò èììóíîìîäóëÿòîð. Àöèêëîâèð æå ðåêîìåíäóþò ïèòü òîëüêî òîãäà, êîãäà ïóçûðüêè ïîÿâëÿþòñÿ(òàê êàê ÿ ìîãó ñïóòàòü ñèìïòîìû è âûïèòü àöèêëîâèð íå ïî äåëó). Ìîå ìíåíèå æå, ÷òî ÿ áåçîøèáî÷íî çíàþ ÷òî áóäåò ðåöèäèâ(íàäåæäû íà òî ÷òî ìåíÿ ãëþ÷èò, íèêîãäà íå îïðàâäûâàþòñÿ, íå ñìîòðÿ íè íà êàêèå ïëàöåáî-âíóøåíèÿ). Íè÷åãî òîëêîì íå ðàçúÿñíÿþò, ñòàâÿò ïå÷àòü â êàðòå è ãîâîðÿò, ÷òî ïèòü ñïèðòíîå+áåðåìåíåòü íåëüçÿ, ÿ äîëæíà ðàñïèñàòüñÿ íà ïå÷àòè, ÷òî ïèòü è áåðåìåíåòü íå áóäó. Ñëåäóþùèé ïðèåì ÷åðåç ìåñÿö-äâà. Ñíîâà èììóíîãðàììû, è íîâûå èììóíîìîäóëÿòîðû. Ñíîâà ðîñïèñü. Ïîòîì îïðåäåëåíèå òèðîâ ê ãåðïåñó. Òèòðû íèçêèå – íàçíà÷åí èììóíîãëîáóëèí. Äîïîëíèòåëüíî ïðîëå÷èâàþòñÿ ñîïóòñòâóþùèå èíôåêöèè. Ãäå-òî ÷åðåç ãîä ÿ çàìåòèëà, ÷òî ðàñïèñûâàëàñü íà ïå÷àòè íå çà òî ÷òî ÿ ïèòü è áåðåìåíåòü íå áóäó, à çà òî ÷òî ÿ îçíàêîìëåíà ñ ïëàíîì ëå÷åíèÿ. Íå ïîäóìàéòå ÷òî ÿ ÷èòàòü íå óìåþ, ïðîñòî ó ìîåãî ëå÷àùåãî âðà÷à, ïå÷àòü íå ïðîïå÷àòûâàëàñü. Ñ ïëàíîì ëå÷åíèÿ ìåíÿ íèêòî íèêîãäà íå çíàêîìèë. À ïîòîì îíè ñãîðåëè âìåñòå ñ ïëàíàìè ëå÷åíèÿ, çàïèñàííûìè äîêòîðîì â êàðòå. Âîò òàêèå äåëà, ðåöèäèâû êàê áûëè , òàê è îñòàëèñü, õîðîøî ÷òî áîëüøå íå ñòàëî. Îáùàÿñü ïî íåòó, è òàêîå ïðèõîäèëîñü ÷èòàòü(ðåöèäèâû ñòàëè ïîñòîÿííûìè). Äåíåã è âðåìåíè íà ýòî ëå÷åíèå ïîòðà÷åíî íåìåðåííî. Íî ÿ âîò òîëüêî ñåé÷àñ çàäóìàëàñü, ÷òî íèêòî è íèêîãäà íå íàïèñàë íà ãåðïåñ.ðó – «Ìåíÿ âûëå÷èëè â ãåðïåòè÷åñêîì öåíòðå».
|
#74
|
||||
|
||||
Öèòàòà:
TREATMENT OPTIONS FOR GENITAL HERPES Recommended regimen for fi rst clinical episode acyclovir, 200 mg orally, 5 times daily for 7 days OR acyclovir, 400 mg orally, 3 times daily for 7 days OR valaciclovir, 1 g orally, twice daily for 7 days OR famciclovir, 250 mg orally, 3 times daily for 7 days Recommended regimen for recurrent infection acyclovir, 200 mg orally, 5 times daily for 5 days OR acyclovir, 400 mg orally, 3 times daily for 5 days OR acyclovir, 800 mg orally, twice daily for 5 days OR valaciclovir, 500 mg orally, twice daily for 5 days OR valaciclovir, 1000 mg orally, once daily for 5 days OR famciclovir, 125 mg orally, twice daily for 5 days Recommended regimen for suppressive therapy acyclovir, 400 mg orally, twice daily, continuously OR valaciclovir, 500 mg orally, once daily OR valaciclovir, 1000 mg orally, once daily OR famciclovir, 250 mg orally, twice daily Note Some experts recommend discontinuing acyclovir after one year of continuous use so that the recurrence rate can be reassessed. The lowest continuous dose that will suppress recurrences in an individual can only be determined empirically. Recommended regimen for severe disease acyclovir, 5–10 mg/kg IV, every 8 hours for 5–7 days or until clinical resolution is attained Recommended regimen in severe herpes simplex lesions with coinfection with HIV acyclovir, 400 mg orally, 3–5 times daily until clinical resolution is attained Recommended regimen for neonates acyclovir, 10 mg/kg intravenously, 3 times a day for 10–21 days È ÍÈÊÀÊÈÕ ÈÌÌÓÍÎÌÎÄÓËßÒÎÐÎÂ Ñïåöèàëüíî äëÿ jedi ââñ [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#75
|
||||
|
||||
Ïîõîæå, â íàøåé áîëüíèöå ïîðà îòêðûòü ïàëàòó ëîðäîâ.
|